European Journal of Nuclear Medicine and Molecular Imaging

European Journal of Nuclear Medicine and Molecular Imaging is a monthly hybrid journal published by Springer and founded in 1976, the official journal of the European Association of Nuclear Medicine, covering clinical nuclear medicine, molecular imaging and the underlying physical and radiochemical sciences, with a 2025 Journal Impact Factor of 7.6 and a first-quartile rank of 12 of 217 in radiology, nuclear medicine and medical imaging《欧洲核医学与分子影像杂志》（European Journal of Nuclear Medicine and Molecular Imaging）是（Springer）出版的月刊，1976 年创刊，为（European Association of Nuclear Medicine）的官方期刊，覆盖临床核医学、分子影像以及相关的物理与放射化学基础，2025 年影响因子为 7.6，在放射学、核医学与医学影像类 217 种期刊中列第 12 位，居第一四分位。

Scope

• Functional, metabolic and molecular investigation of disease is the journal's central subject, with positron emission tomography and single-photon emission imaging at its core疾病的功能、代谢与分子层面研究是该刊的核心主题，正电子发射断层与单光子发射成像居于中心位置。
• Clinical oncology applications are covered broadly, including staging, treatment response assessment and radionuclide therapy临床肿瘤学应用得到广泛覆盖，包括分期、疗效评估与放射性核素治疗。
• Radiochemistry and radiopharmacy are within scope, from tracer synthesis and quality control to the translation of new probes into first-in-human studies放射化学与放射药学属于收稿范围，从示踪剂合成、质量控制到新探针的首次人体研究转化。
• Physics, dosimetry and radiation biology are treated as essential parts of the field rather than ancillary topics物理、剂量学与放射生物学被视为该领域不可或缺的组成部分，而非附属议题。
• Molecular imaging probes, reporter gene assays and cell-trafficking studies fall within the journal's longstanding interests分子影像探针、报告基因检测与细胞迁移研究属于该刊长期关注的方向。
• Quantitative imaging, instrumentation and artificial intelligence methods are increasingly represented, alongside guidelines and procedural recommendations from the sponsoring society定量影像、仪器与人工智能方法所占比重不断增加，同时刊载主办学会的指南与操作规范。

History

• The journal began in 1976 as the European Journal of Nuclear Medicine, published by Springer and serving a fast-growing European nuclear medicine community该刊 1976 年以（European Journal of Nuclear Medicine）之名创刊，由（Springer）出版，服务当时快速成长的欧洲核医学界。
• It took its present title when molecular imaging was added to the name in 2002, reflecting the shift from organ-based scintigraphy to probe-based imaging2002 年刊名加入分子影像字样并改为现名，反映该领域由器官显像转向探针显像的变化。
• EJNMMI Research was launched in 2011 as an open-access companion for studies that could not be accommodated in the main journal2011 年创办开放获取的姊妹刊（EJNMMI Research），用于发表主刊难以容纳的研究。
• The title is the anchor of the EJNMMI family of journals, which shares editorial standards and an annual award with the European Association of Nuclear Medicine该刊是（EJNMMI）系列期刊的核心，与（EANM）共享编辑标准并共同设立年度奖项。
• The Journal Impact Factor was 9.236 in 2021 and 10.057 in 2022, then 7.6 in both 2024 and 2025该刊影响因子 2021 年为 9.236，2022 年为 10.057，2024 年与 2025 年均为 7.6。
• The journal is indexed in Science Citation Index Expanded, MEDLINE, EMBASE, Scopus and INIS Atomindex, among other databases该刊被（SCIE）、（MEDLINE）、（EMBASE）、（Scopus）与（INIS Atomindex）等数据库收录。

Editors

• The editor-in-chief is Arturo Chiti, professor at Humanitas University and head of nuclear medicine at the Humanitas Clinical and Research Center in Milan主编为（Humanitas University）教授（Arturo Chiti），他同时任米兰（Humanitas Clinical and Research Center）核医学科主任。
• Kuangyu Shi and Axel Rominger, both of the University of Bern, serve as editors and handle imaging physics, artificial intelligence and neurology-related submissions（University of Bern）的（Kuangyu Shi）与（Axel Rominger）任编辑，负责影像物理、人工智能与神经相关稿件。
• The editorial board is drawn from the European nuclear medicine community and from corresponding centres in Asia and North America编委会成员来自欧洲核医学界以及亚洲与北美的对口机构。
• Manuscripts are assessed by the editors and external referees, with reviewer identities withheld from authors稿件由编辑与外部审稿人评估，审稿人身份不向作者披露。
• Publication follows the hybrid model, so authors may choose open access against payment or publish on the subscription track at no charge该刊采用混合出版模式，作者可付费选择开放获取，也可在订阅模式下免费发表。